Transcription factors control the genetic programs that maintain cellular balance, but while they have been seen as compelling targets for aging-related disease, they have long been considered “undruggable.” Junevity’s RESET platform leverages large-scale human omics data and AI models to pinpoint key transcriptional drivers of disease and to design siRNA therapies that restore healthy gene expression.​ We spoke to John Hoekman, co-founder and CEO of Junevity, about the role of transcription factors in healthy biology and aging-related disease, the company’s AI-driven platform for identifying dysregulated transcription factors, and its lead programs targeting type 2 diabetes and obesity.

Ver todos los episodios